248 related articles for article (PubMed ID: 20082957)
1. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies.
Naldi L
Clin Dermatol; 2010; 28(1):88-92. PubMed ID: 20082957
[TBL] [Abstract][Full Text] [Related]
2. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
3. Comparative tolerability of systemic treatments for plaque-type psoriasis.
McClure SL; Valentine J; Gordon KB
Drug Saf; 2002; 25(13):913-27. PubMed ID: 12381213
[TBL] [Abstract][Full Text] [Related]
4. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
[TBL] [Abstract][Full Text] [Related]
5. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
Naldi L; Griffiths CE
Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
[TBL] [Abstract][Full Text] [Related]
6. The risk of melanoma and hematologic cancers in patients with psoriasis.
Reddy SP; Martires K; Wu JJ
J Am Acad Dermatol; 2017 Apr; 76(4):639-647.e2. PubMed ID: 27876302
[TBL] [Abstract][Full Text] [Related]
7. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
8. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.
Feldman SR; Garton R; Averett W; Balkrishnan R; Vallee J
Expert Opin Pharmacother; 2003 Sep; 4(9):1525-33. PubMed ID: 12943482
[TBL] [Abstract][Full Text] [Related]
9. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Paul CF; Ho VC; McGeown C; Christophers E; Schmidtmann B; Guillaume JC; Lamarque V; Dubertret L
J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
[TBL] [Abstract][Full Text] [Related]
10. Phototherapy for psoriasis.
Hönigsmann H
Clin Exp Dermatol; 2001 Jun; 26(4):343-50. PubMed ID: 11422187
[TBL] [Abstract][Full Text] [Related]
11. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
12. A 61-year-old man with psoriasis.
Baughman RD
JAMA; 1996 Nov; 276(17):1421-8. PubMed ID: 8892718
[No Abstract] [Full Text] [Related]
13. [Prescription of phototherapy in psoriasis].
Beani JC
Rev Prat; 2004 Jan; 54(1):43-7. PubMed ID: 15049599
[TBL] [Abstract][Full Text] [Related]
14. Adverse events from systemic therapies for psoriasis are common in clinical practice.
Pearce DJ; Higgins KB; Stealey KH; Balkrishnan R; Crane MM; Camacho F; Fleischer AB; Feldman SR
J Dermatolog Treat; 2006; 17(5):288-93. PubMed ID: 17092859
[TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
16. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
Shear NH
Drug Saf; 2006; 29(1):49-66. PubMed ID: 16454534
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic strategies against psoriasis. Skin to hide -- and how do you free your patients from it].
Stiefelhagen P
MMW Fortschr Med; 2007 Sep; 149(35-36):12-4. PubMed ID: 17944277
[No Abstract] [Full Text] [Related]
18. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Geller S; Xu H; Lebwohl M; Nardone B; Lacouture ME; Kheterpal M
Am J Clin Dermatol; 2018 Jun; 19(3):363-375. PubMed ID: 29260411
[TBL] [Abstract][Full Text] [Related]
19. PUVA, UVB, psoriasis, and nonmelanoma skin cancer.
Studniberg HM; Weller P
J Am Acad Dermatol; 1993 Dec; 29(6):1013-22. PubMed ID: 8245237
[TBL] [Abstract][Full Text] [Related]
20. [Current treatment of psoriasis].
Karvonen J
Duodecim; 2000; 116(24):2769-75; quiz 2776, 2787. PubMed ID: 12077879
[No Abstract] [Full Text] [Related]
[Next] [New Search]
